Seizure Activity after Venlafaxine Overdose

Journal of Pharmacy Technology

Volumn 19, Issue 6, 2003, Pages 358-360

  Sarandöl, Asli ^a   Taneli, Bilgen ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED CARBON; ALANINE AMINOTRANSFERASE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ASPARTATE AMINOTRANSFERASE; DIAZEPAM; MIRTAZAPINE; PHENYTOIN; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; DRUG CAPSULE; DRUG EFFECT; DRUG OVERDOSE; ELECTROENCEPHALOGRAM; HUMAN; INGESTION; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR DEPRESSION; MALE; MENTAL DISEASE; SEIZURE; SUICIDE ATTEMPT; TONIC CLONIC SEIZURE;

EID: 0346734268     PISSN: 87551225     EISSN: None     Source Type: Journal    
DOI: 10.1177/875512250301900604     Document Type: Article

References (30)

1. Andrews JM, Ninan PT, Nemeroff CB. Venlafaxine: a novel antidepressant that has a dual mechanism of action. Depression 1996; 4:48-56.
2. Holliday SM, Benfield P. Venlafaxine: a review of its pharmacology and therapeutic potential. Drugs 1995;49:280-94.
3. Donjou P, Hackett D. Safety and tolerance profile of venlafaxine. Int Clin Psychopharmacol 1995;10(suppl 2):15-20.
4. Rudolph RL, Derivan AT, Khan A. The safety and tolerability of venlafaxine hydrochloride: analysis of clinical trials database. J Clin Psychopharmacol 1996;16(suppl 2):54-61.
5. Buckley NA, McManus PR. Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. BMJ 2002;325:1332-3.
6. Whyte IM, Dawson AH, Buckley NA. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. Q J Med 2003;96:369-74.
7. Peano C, Leikin JB, Hanashiro PK. Seizures, ventricular tachycardia, and rhabdomyolysis as a result of ingestion of venlafaxine and lamotrigine. Ann Emerg Med 1997;30:704-8.
8. Durback LF, Scharman EJ. Comment: seizure resulting from venlafaxine overdose (letter). Ann Pharmacother 1997;31:790-1.
9. White CM, Gailey RA, Levin GM, Smith T. Seizure resulting from a venlafaxine overdose. Ann Pharmacother 1997;31:178-80.
10. Zhalkovsky B, Walker D, Bougeois JA. Seizure activity and enzyme elevations after venlafaxine overdose (letter). J Clin Psychopharmacol 1997;17:490-1.
11. Leaf EV. Comment: venlafaxine overdose and seizure (letter). Ann Pharmacother 1998;32:135-6.
12. Coorey AN, Wenck DJ. Venlafaxine overdose (letter). Med J Aust 1998;168:523.
13. Blythe D, Hackett LP. Cardiovascular and neurological toxicity of venlafaxine. Hum Exp Toxicol 1999;18:309-13.
14. Jaffe PD, Batziris HP, Van der Hoeven P, DeSilva D, McIntyre IM. A study involving venlafaxine overdoses: comparison of fatal and therapeutic concentrations in postmortem specimens. J Forensic Sci 1999;44:193-6.
15. Parsons AT, Anthony RM, Meeker JE. Two fatal cases of venlafaxine poisoning. J Anal Toxicol 1996;20:266-8.
16. Montgomery SA. Venlafaxine: a new dimension in antidepressant pharmacotherapy. J Clin Psychiatry 1993;54:119-26.
17. Durback LF, Scharman EJ. Seizure associated with venlafaxine overdose (abstract). J Toxicol Clin Toxicol 1996;34:557.
18. Peano C, Wahl M, Keyes N, Leikin JB. Seizures and ventricular tachycardia secondary to venlafaxine and lamotrigine (abstract). J Toxicol Clin Toxicol 1996;34:558.
19. Kokan L, Dart RC. Life-threatening hypotension from venlafaxine overdose (abstract). J Toxicol Clin Toxicol 1996;34:559.
20. Colbridge MG, Volans GN. Venlafaxine in overdose - experience of the National Poisons Information Service (London centre). EAPCCT XIX International Congress (abstract). J Toxicol Clin Toxicol 1999;37:383.
21. Klamerus KJ, Maloney K, Rudolph RL, Sisenwine SF, Jusko WJ, Chiang ST. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J Clin Psychopharmacol 1992;32:716-24.
22. Langford NJ, Martin U, Ruprah M, Ferner RE. Alternative venlafaxine kinetics in overdose. J Clin Pharm Ther 2002;27:465-7.
23. Bourin M. Psychopharmacology profile of venlafaxine. Encephale 1999;25:21-5.
24. Santos JG Jr, Do Monte FHM, Russi M, Agustine PE, Lanziotti VMNB. Proconvulsant effects of high doses of venlafaxine in pentyltetrazole-convulsive rats. Braz J Med Biol Res 2002;35:469-72.
25. Khalifa M, Daleau P, Turgeon J. Mechanism of sodium channel block by venlafaxine in guinea pig ventricular myocytes. J Pharmacol Exp Ther 1999;291:280-4.
26. Vandel P, Haffen E, Vandel S, Bonin B, Nezelof S, Sechter D, et al. Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes. Eur J Clin Pharmacol 1999;55:659-65.
27. Micromedex. Healthcare series. Vol. 116. Greenwood Village, CO: Micromedex, 2003.
28. Dimellis D. Serotonin syndrome produced by a combination of venlafaxine and mirtazapine (letter). World J Biol Psychiatry 2002;3:167.
29. Montgomery SA. Safety of mirtazapine: a review. Int Clin Psychopharmacol 1995;10(suppl 4):37-45.
30. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.